Authors: Payne, R Coluzzi, P Hart, L Simmonds, M Lyss, A Rauck, R Berris, R Busch, MA Nordbrook, E Loseth, DB Portenoy, RK

Citation: R. Payne et al., Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain, J PAIN SYMP, 22(1), 2001, pp. 575-583

Authors: Raschko, JW Synold, TW Chow, W Coluzzi, P Hamasaki, V Leong, LA Margolin, KA Morgan, RJ Shibata, SI Somlo, G Tetef, ML Yen, Y ter Veer, A Doroshow, JH

Citation: Jw. Raschko et al., A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A, CANC CHEMOT, 46(5), 2000, pp. 403-410

Authors: Portenoy, RK Payne, R Coluzzi, P Raschko, JW Lyss, A Busch, MA Frigerio, V Ingham, J Loseth, DB Nordbrock, E Rhiner, M

Citation: Rk. Portenoy et al., Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study, PAIN, 79(2-3), 1999, pp. 303-312

Authors: Morgan, RJ Braly, P Cecchi, G Leong, L Shibata, S Margolin, K Somlo, G McNamara, M Longmate, J Schinke, S Raschko, J Nagasawa, S Kogut, N Parker, P Stein, A Cho, J Smith, E Coluzzi, P Najera, L Johnson, D Womack, E Doroshow, JH

Citation: Rj. Morgan et al., Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up, GYNECOL ONC, 75(3), 1999, pp. 419-426